Hypertension, Resistant to Conventional Therapy
Conditions
Keywords
minocycline, blood pressure
Brief summary
The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.
Detailed description
One hundred twenty patients with treatment-resistant hypertension will be enrolled. A total of 34 patients (17 from each treatment arm), who are participants in the main study, will also be enrolled in a substudy that includes neuroimaging. The study will last 3 months, and will include 3 visit time points (screening, randomization visit, 3-month follow-up visit). Participants will be randomly assigned, in a 1:1 allocation, to minocycline 100 mg twice per day, or matching placebo, each provided by the study, and investigators will be blinded to treatment assignment. At the baseline and 3-month follow-up visit, subjects will undergo: * A comprehensive medical history and examination, including assessment of antihypertensive treatment history * A series of behavioral activity questionnaires * Blood tests (plasma renin activity, aldosterone, catecholamines, serum creatinine, lipid panel, hemoglobin a1c, as well as various biomarkers of immune and inflammatory activity, and gut leakiness markers) * Urine/saliva tests for antihypertensive adherence * Gut microbiota profiling via whole metagenomic sequencing of stool samples * Blood pressure (BP) measurement, including unattended office BP and 24-hour ambulatory BP Subjects enrolled in the neuroimaging substudy will also have PET/MR imaging performed at each visit. Neuroimaging activities will take place at Emory University in Atlanta, GA. At the final visit (3-month follow-up), participants will also have blood tests to measure study drug concentration, as a measure of adherence to the assigned treatment.
Interventions
Minocycline Hydrochloride 100 mg twice daily
DRUGPlacebo
Placebo
Sponsors
University of Florida
Emory University
National Heart, Lung, and Blood Institute (NHLBI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic. * The participant agrees to have all study procedures performed
Exclusion criteria
* Known hypersensitivity or contraindication to minocycline or other tetracyclines * Recent (≤3 months prior), ongoing, or expected use of oral antibiotics * Estimated glomerular filtration rate (eGFR) of \<45mL/min/1.73m2, using the MDRD equation * Known secondary hypertension * History of hypertensive crisis, defined as any in-patient hospitalizations for hypertensive crisis/emergency within the past year * History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of \>20 mm Hg or DBP of \>10 mm Hg within 3 minutes of standing) in the past year * History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months * Evidence of alcoholism or drug abuse * Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS) * Current pregnancy or anticipated pregnancy during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 24-h systolic blood pressure | 3 months | Change in mean 24-hour ambulatory systolic blood pressure |
| Gut microbiome | 3 months | Change in butyrate-producing gene abundance |
| Gut inflammation and leakiness | 3 months | Change in gut-homing inflammatory T-helper cells |
| Neuroinflammation | 3 months | Change in \[18F\]FEPPA radiotracer uptake on PET/MR imaging |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mucin-degrading gene abundance | 3 months | Change in mucin-degrading gene abundance |
| IgA+ coated plasma cells | 3 months | Change in IgA+ coated plasma cells |
| Gut leakiness markers | 3 months | Change in gut leakiness markers, including lipocalin-2, intestinal fatty-acid binding protein (I-FABP), zonulin, and lipopolysaccharides (LPS) |
| 24-h diastolic blood pressure | 3 months | Change in mean 24-hour diastolic blood pressure |
| 24-h heart rate | 3 months | Change in mean 24-hour heart rate |
| Adverse Events | 3 months | Incidence of treatment-related adverse events |
Countries
United States
Contacts
CONTACTJoshua N Terrell
CONTACTDavid B Smith
PRINCIPAL_INVESTIGATORSteven M Smith, PharmD, MPH
University of Florida
Outcome results
None listed